GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Aspira Pathlab & Diagnostics Ltd

Aspira Pathlab: Board Approves Half-Yearly Financial Results for Q2 FY27

RESULTS ● No Immediate Change LOW RISK
📅 Filed on BSE: 06 Nov 2026, 04:50 PM IST  ·  BSE ID: bd62da51-5eb1-438f-bba9-e4af5e3b1700
View Original BSE Filing (PDF)
💡
In Simple Terms
Aspira Pathlab's board approved its financial results for the quarter and half-year ending September 30, 2026.
🤖 AI Summary
  • Aspira Pathlab & Diagnostics Board approved Un-Audited Standalone Financial Results for Q2 FY27 and half-year ended September 30, 2026.
  • Board Meeting held on November 06, 2026, commenced at 01:30 P.M (IST) and concluded at 04:00 P.M. (IST).
  • No outstanding defaults reported on loans/revolving facilities from banks/financial institutions as of September 30, 2026.
  • No outstanding defaults on unlisted debt securities (NCDs and NCRPS) as of September 30, 2026.
  • Total financial indebtedness, including short-term and long-term debt, was ₹0 crore as of September 30, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Total amount outstanding on loans/revolving facilities as on September 30, 2026
₹0 crore
Amount of default on loans/revolving facilities as on September 30, 2026
₹0 crore
Total amount outstanding on unlisted debt securities as on September 30, 2026
₹0 crore
Amount of default on unlisted debt securities as on September 30, 2026
₹0 crore
Total financial indebtedness as on September 30, 2026
₹0 crore
🏢 How This Affects the Company
💰
Financial Impact
The company reported no outstanding defaults on loans, revolving facilities, or unlisted debt securities, indicating a debt-free status for these categories as of September 30, 2026. Total financial indebtedness stood at ₹0 crore.
⚠️
Risk Impact
The disclosure of zero outstanding debt and no defaults on loans/debt securities as of September 30, 2026, decreases financial risk related to leverage and default for the company.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this specific filing.
👤
Who Is Affected
All shareholders are indirectly affected by the board's approval of financial results, as these results will detail the company's performance for Q2 FY27 and the half-year.
🔍
Management Signal
The management's filing indicates adherence to SEBI (LODR) Regulations, 2015, and a commitment to transparency by reporting the approval of financial results and current debt status.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Review the detailed Un-Audited Standalone Financial Results for Q2 FY27 once released.
Monitor future filings for any significant changes in the company's financial indebtedness.
Track disclosures regarding operational updates or business expansion initiatives.
LOW RISK The filing indicates a debt-free status as of September 30, 2026, which reduces financial leverage risk.
💡 Investor Takeaway
Aspira Pathlab & Diagnostics Limited's Board approved its Un-Audited Standalone Financial Results for the half-year ended September 30, 2026 (Q2 FY27). The company reported no outstanding defaults on loans, debt securities, or any total financial indebtedness, with all figures at ₹0 crore as of September 30, 2026.
⚖️ Strengths & Concerns

✅ Positives

  • The company reported zero outstanding defaults on loans/revolving facilities from banks/financial institutions as of September 30, 2026.
  • Aspira Pathlab & Diagnostics Limited has a total financial indebtedness of ₹0 crore as of September 30, 2026, including short-term and long-term debt.
❓ Frequently Asked Questions
What financial results did Aspira Pathlab & Diagnostics' Board approve?
Aspira Pathlab & Diagnostics' Board approved the Un-Audited Standalone Financial Results for the second quarter and half-year ended September 30, 2026.
What is Aspira Pathlab's total financial indebtedness as of September 30, 2026?
Aspira Pathlab & Diagnostics Limited reported a total financial indebtedness of ₹0 crore as of September 30, 2026, including short-term and long-term debt.
Did Aspira Pathlab & Diagnostics report any defaults on loans or debt securities?
No, Aspira Pathlab & Diagnostics Limited reported ₹0 crore in outstanding defaults on loans, revolving facilities, and unlisted debt securities as of September 30, 2026.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.